A Randomized Phase II Study of Sequential Biotherapy With Aflibercept and High Dose IL-2 Versus High Dose IL-2 Alone in Patients With Inoperable Stage III or Stage IV Melanoma: Efficacy and Biomarker Study.
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Aldesleukin (Primary) ; Aflibercept
- Indications Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 02 Apr 2018 Status changed from active, no longer recruiting to completed.
- 11 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2018.
- 10 Jun 2017 Biomarkers information updated